TY - JOUR
T1 - Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma
AU - Xu, Baogang J.
AU - An, Qi A.
AU - Gowda, Supriya Srinivasa
AU - Yan, Wenwei
AU - Pierce, Larry A.
AU - Abel, Ty W.
AU - Rush, Sarah Z.
AU - Cooper, Michael K.
AU - Ye, Fei
AU - Shyr, Yu
AU - Weaver, Kyle D.
AU - Thompson, Reid C.
PY - 2012/6
Y1 - 2012/6
N2 - Analyzing molecular biomarkers using blood is an important approach for clinical assessment of malignant glioma. We investigated a molecular proteomic biomarker-based approach for glioblastoma using patients' blood samples. The expression levels of a list of candidate proteins were quantified in plasma and serum samples from two different cohorts of patients with malignant glioma and normal controls. The biological function was studied for one of the identified markers. Additionally, the prognostic significance of protein marker expression was measured by survival analysis. As a result, protein biomarkers associated with malignant glioma were identified from the blood specimens and five of the protein biomarkers were common to both cohorts. Immunohistochemical analysis demonstrated that many of the protein biomarkers identified in peripheral blood specimens were expressed in malignant gliomas. Staining levels for one of the biomarkers, MIP-1α, was found to correlate with WHO grade among invasive gliomas, and we demonstrate that MIP-1α promotes human glioblastoma cell proliferation and migration. Additionally, four prognostic protein biomarkers were identified. In conclusion, we demonstrate that both peripheral blood plasma and serum specimens are highly valuable and complementary to each other in the quest for protein biomarkers of malignant glioma. Sets of novel protein biomarkers were identified that may aid in the diagnosis and prognosis of patients with malignant glioma.
AB - Analyzing molecular biomarkers using blood is an important approach for clinical assessment of malignant glioma. We investigated a molecular proteomic biomarker-based approach for glioblastoma using patients' blood samples. The expression levels of a list of candidate proteins were quantified in plasma and serum samples from two different cohorts of patients with malignant glioma and normal controls. The biological function was studied for one of the identified markers. Additionally, the prognostic significance of protein marker expression was measured by survival analysis. As a result, protein biomarkers associated with malignant glioma were identified from the blood specimens and five of the protein biomarkers were common to both cohorts. Immunohistochemical analysis demonstrated that many of the protein biomarkers identified in peripheral blood specimens were expressed in malignant gliomas. Staining levels for one of the biomarkers, MIP-1α, was found to correlate with WHO grade among invasive gliomas, and we demonstrate that MIP-1α promotes human glioblastoma cell proliferation and migration. Additionally, four prognostic protein biomarkers were identified. In conclusion, we demonstrate that both peripheral blood plasma and serum specimens are highly valuable and complementary to each other in the quest for protein biomarkers of malignant glioma. Sets of novel protein biomarkers were identified that may aid in the diagnosis and prognosis of patients with malignant glioma.
UR - http://www.scopus.com/inward/record.url?scp=84861775751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84861775751&partnerID=8YFLogxK
U2 - 10.3892/ijo.2012.1355
DO - 10.3892/ijo.2012.1355
M3 - Article
C2 - 22307528
AN - SCOPUS:84861775751
SN - 1019-6439
VL - 40
SP - 1995
EP - 2003
JO - International Journal of Oncology
JF - International Journal of Oncology
IS - 6
ER -